高级检索
当前位置: 首页 > 详情页

Construction and validation of a necroptosis-related prognostic signature in acute myeloid leukemia

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Clinical Laboratory,the First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,P.R. China, [2]Yunnan Key Laboratory of Laboratory Medicine, Kunming, Yunnan, P.R. China, [3]Yunnan Innovation Team of Clinical Laboratory and Diagnosis,the First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,P.R. China, [4]Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, Yunnan, P.R. China [5]Department of Clinical Laboratory, the Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, P.R. China.
出处:
ISSN:

关键词: acute myeloid leukemia necroptosis prognosis TCGA

摘要:
Acute myeloid leukemia (AML), an uncommonly low 5-year survival and high mortality rate, is a potentially catastrophic diagnosed subtype of leukemia. The development of new prognostic markers is urgently needed to guide its treatment. Necroptosis is a newly defined biological process for regulating cell death, and previous studies have confirmed that the abnormality of the physical function can lead to multiple malignancies. Here, we performed necroptosis-related genes (NRGs) to build a predictive model in the Cancer Genome Atlas (TCGA)-AML patients, thus exploring the correlation between the NRG prognosis signature (NRG score) of this model and immune infiltration, pathway activity, clinical features, and immunotherapy. Besides, we computed the statistical measure Spearman rank correlation between the NRG score and the Log IC50 values of therapeutic agents. Subsequently, we divided the TCGA-AML cohort into 2 groups, one with high scores and the other with low scores depending on the model score. AML patients with high NRG scores exhibited a lower estimated overall survival (OS) rate than those with low NRG scores, which was confirmed in the validation set. The prognostic value of the constructed NRG signature to the AML, independent of other variables, was demonstrated by uni- and multivariate stepwise regression analysis. When comparing the infiltrating states of specialized cells associated with immune system from the 2 groups, B cells naive, Plasma cells, and monocytes represented significant differences among various subgroups of samples. Moreover, the 30 hallmark-related pathways related to necroptosis characteristics were remarkably different between the high/low NRG score groups. And patients showed remarkable NRG score distribution in clinical features of bone marrow lymphocyte, category, and FAB classifications. Besides, we found that the BIRB0796, VX680, Vorinostat, and Axitinib positively related with NRG score, whereas CI. 1040, PD. 0325901, Z.L LNle. CHO, and AZD6244 negatively correlated with the NRG score. These drugs may provide a reference for subsequent treatment.

基金:
语种:
WOS:
中科院(CAS)分区:
出版当年[2025]版:
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Department of Clinical Laboratory,the First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,P.R. China, [2]Yunnan Key Laboratory of Laboratory Medicine, Kunming, Yunnan, P.R. China, [3]Yunnan Innovation Team of Clinical Laboratory and Diagnosis,the First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,P.R. China, [4]Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, Yunnan, P.R. China
通讯作者:
通讯机构: [1]Department of Clinical Laboratory,the First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,P.R. China, [2]Yunnan Key Laboratory of Laboratory Medicine, Kunming, Yunnan, P.R. China, [3]Yunnan Innovation Team of Clinical Laboratory and Diagnosis,the First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,P.R. China, [4]Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, Yunnan, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52537 今日访问量:0 总访问量:1562 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)